Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer

NCT ID: NCT07179809

Last Updated: 2025-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-28

Study Completion Date

2029-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective:

Assess the feasibility of delivering the ACLP, ACLP-LC, and ACLP-LC-IHC programs in stable HR+/HER2- MBC survivors. Feasibility criteria will include the percent of eligible patients who consent to participate (feasibility is defined as 30% of those approached and are eligible end up consenting) and study retention by the last follow-up (feasibility is defined as 50% of those randomized remaining in the study and who participated in at least 75% of online sessions). Our working hypothesis is that the provision of the evidence-based, mHeath ACLP with the Learning Circle support group, with or without individual health coaching, is feasible in patients with stable HR+/HER2- MBC.

Secondary Objectives:

1. Explore changes in targeted health behaviors of diet, exercise, and stress management.
2. Examine changes in patient-reported outcomes (PROs), including: QOL, fatigue, sleep disturbances, mental health, social support, mindfulness, and stages of change.
3. Examine if there are group differences in post-intervention albumin, vit D, and magnesium levels.

OUTLINE: Patients are first randomized to 1 of 3 groups.

GROUP 1 (ACLP): Patients receive an outline of tasks and complete ACLP interactive exercise and activity modules on their own over 8 weeks and receive calls weekly for 8 weeks.

GROUP 2 (ACLP-LC): Patients complete ACLP interactive exercise and activity modules and attend online LC group sessions over 90 minutes once weekly (QW) for 8 weeks. Patients receive informational emails weekly prior to scheduled sessions.

GROUP 3 (ACLP-LC-IHC): Patients participate in the 8-week ACLP-LC program just like group 2. In addition, starting two weeks after the end of the program, they receive IHC sessions over 30-60 minutes for up to 6 sessions over 3 months.

Additionally, patients undergo blood sample collection throughout the study.

After completion of study treatment, patients are followed at 3 and 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACLP Program

Participants will take part in the ACLP alone

Group Type EXPERIMENTAL

Demographics/Lifestyle Survey

Intervention Type OTHER

Participants will complete all sessions and instruments

ACLP Program + Learning Circles

Participants will take part in the ACLP and Learning Circles

Group Type EXPERIMENTAL

Demographics/Lifestyle Survey

Intervention Type OTHER

Participants will complete all sessions and instruments

ACLP Program + Learning Circles + Individual Health Coaching

Participants will take part in the ACLP and in Learning Circles After participants complete the ACLP with Learning Circles, they will receive up to 6 individualized health coaching sessions.

Group Type EXPERIMENTAL

Demographics/Lifestyle Survey

Intervention Type OTHER

Participants will complete all sessions and instruments

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Demographics/Lifestyle Survey

Participants will complete all sessions and instruments

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with HR+/HER2 negative MBC
2. On first- or second-line treatment
3. Life expectancy at least 12 months
4. Only females
5. Age 18 years or older
6. Able to read, write, and speak English
7. Willingness to follow protocol requirements
8. Have a smartphone with access to cellular service or computer access with internet service
9. Oriented to person, place, and time
10. Consume less than 3 servings of fruit and vegetable/day
11. Engage in less than 150 minutes moderate/vigorous intensity activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling)
12. Engage in a mind-body practice less than 4 times a month

Exclusion Criteria

1. Another primary cancer diagnosis within past 5 years (not including non-melanoma skin cancers)
2. Any major thought disorder (e.g., schizophrenia, dementia)
3. Communication barriers (e.g., hard of hearing)
4. Poorly-controlled or uncontrolled diabetes in the opinion of the physician(s)
5. Extreme mobility issues (e.g., unable to get in and out of a chair unassisted)
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Meroe Morse, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Meroe Morse, MD

Role: CONTACT

713-794-4053

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Meroe Morse, MD

Role: primary

713-794-4053

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

MD Anderson Cancer Center Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2025-06338

Identifier Type: OTHER

Identifier Source: secondary_id

2025-0951

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Couples' QOL in Metastatic Breast Cancer
NCT05636943 ACTIVE_NOT_RECRUITING NA